| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA691221 | F | Anti-HRV activity against HRV serotype 39 | rhinovirus A39 | 3 | ALA1144873 | organism-based format | Scientific Literature | |
| 2. | ALA1027970 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 1 passage for 7 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 3. | ALA1027971 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 2 passages for 12 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 4. | ALA1027972 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 3 passages for 14 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 5. | ALA1027973 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 4 passages for 24 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 6. | ALA1027974 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 5 passages for 29 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 7. | ALA1027975 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 6 passages for 33 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 8. | ALA1027976 | F | Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 9. | ALA1027977 | F | Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 10. | ALA1027978 | F | Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 7 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 11. | ALA1028776 | F | Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 12 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 12. | ALA1028777 | F | Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 13. | ALA1028778 | F | Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 14. | ALA1028779 | F | Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 15. | ALA1028780 | F | Antiviral activity against HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 33 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 16. | ALA1028781 | F | Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 17. | ALA1028782 | F | Ratio of EC50 for HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells after 5 passages for 29 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 18. | ALA1028783 | F | Ratio of EC50 for HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells | rhinovirus A39 | 1 | ALA1151438 | organism-based format | Scientific Literature | |
| 19. | ALA1663000 | F | Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay | rhinovirus A39 | 2 | ALA1649184 | organism-based format | Scientific Literature | |
| 20. | ALA2411604 | F | Antienteroviral activity against Human rhinovirus 39 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | rhinovirus A39 | 2 | ALA2407051 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!